RSC Pharmaceutics最新文献_第10页

The potential of small extracellular vesicles for pancreatic cancer therapy 小细胞外囊泡在胰腺癌治疗中的潜力

RSC Pharmaceutics Pub Date : 2025-08-06 DOI: 10.1039/D5PM00115C

Richard Crow, Oksana Kehoe and Clare Hoskins

{"title":"The potential of small extracellular vesicles for pancreatic cancer therapy","authors":"Richard Crow, Oksana Kehoe and Clare Hoskins","doi":"10.1039/D5PM00115C","DOIUrl":"https://doi.org/10.1039/D5PM00115C","url":null,"abstract":"Extracellular vesicles come in various shapes and sizes and are released by most cell types. They have myriad roles in intercellular signalling in both physiological and pathological environments, carrying a range of lipids, proteins and nucleic acids. Their cargo is then unloaded at the target site inducing a change in their target cell. Cancers use these vesicles to their advantage for a wide range of outcomes such as immune evasion and chemoresistance leading to the reduced effect of chemotherapies and unfavourable patient outcomes. Pancreatic cancer has one of the worst outcomes of any cancer with surgery being the only cure. As surgery is only available in a small number of cases, targeted delivery of cargos directly to the tumour site is of high importance to efficiently target and destroy cancer cells with high effectiveness without the toxic off-target effects of chemotherapy drugs. Hijacking the body's postal system has gained interest in the last decade for the delivery of therapeutic drugs. The low immunogenicity and inherent biocompatibility of extracellular vesicles avoids the hurdles experienced by other nanoparticles such as toxicity. Various techniques for loading and functionalising extracellular vesicles have progressed to clinical trials, however, these therapies are yet to make it onto the market. This review seeks to be a call to action to the pancreatic cancer community, highlighting the potential of these biologic systems in the improvement of therapeutic outcomes of what is one of the deadliest cancers.","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 5","pages":" 1034-1049"},"PeriodicalIF":0.0,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2025/pm/d5pm00115c?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitigating oxidative stress in red blood cells with quercetin-loaded liposomes: a promising strategy 用槲皮素脂质体减轻红细胞氧化应激：一个有前途的策略

RSC Pharmaceutics Pub Date : 2025-08-05 DOI: 10.1039/D5PM00112A

Akshay Kumar, Stuti Bhagat, Kareena Moar, Sanjay Singh and Pawan Kumar Maurya

{"title":"Mitigating oxidative stress in red blood cells with quercetin-loaded liposomes: a promising strategy","authors":"Akshay Kumar, Stuti Bhagat, Kareena Moar, Sanjay Singh and Pawan Kumar Maurya","doi":"10.1039/D5PM00112A","DOIUrl":"https://doi.org/10.1039/D5PM00112A","url":null,"abstract":"Aging is a continuous process that occurs in the body and alters many physiological and cellular functions. It leads to numerous long-term ailments such as cancer, dementia, cardiovascular diseases, etc. To promote healthy aging with secondary metabolites and secondary metabolites encapsulated in liposomes, this study evaluated the effects of quercetin and quercetin-loaded liposomes on the oxidative stress biomarkers (GSH and MDA) of red blood cells, as RBCs deliver oxygen to tissues and are continuously exposed to oxidative stress. Quercetin is a flavonoid and has poor solubility in an aqueous medium; hence to enhance its bioavailability, it was encapsulated in liposomes. In this study, 34 healthy individuals of both sexes took part. An in vitro study was performed with RBCs of different age groups, namely, young, middle, and old. tert-Butyl hydroperoxide (t-BHP) was used as a positive control, while quercetin and quercetin-loaded liposomes were used as treatment agents to check their effects on GSH and MDA levels. The study showed a significant (p < 0.0001) increase in GSH levels and a significant (p < 0.0001) decrease in MDA levels in the case of quercetin-loaded liposomes. The results of the current study indicated the antioxidant role of quercetin-loaded liposomes throughout the aging process. These findings hold significant promise in the area of biomedical research and further investigation is needed to use quercetin-loaded liposomes as a potential anti-aging agent and promote health and disease-free aging.","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 6","pages":" 1471-1478"},"PeriodicalIF":0.0,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2025/pm/d5pm00112a?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145479560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging drug delivery strategies for glaucoma therapy: focus on nanoparticles and stimuli-responsive systems 青光眼治疗的新药物递送策略：关注纳米颗粒和刺激反应系统

RSC Pharmaceutics Pub Date : 2025-08-05 DOI: 10.1039/D5PM00068H

Sourabh Kundu, Gitika Kumari and Dadi A. Srinivasarao

{"title":"Emerging drug delivery strategies for glaucoma therapy: focus on nanoparticles and stimuli-responsive systems","authors":"Sourabh Kundu, Gitika Kumari and Dadi A. Srinivasarao","doi":"10.1039/D5PM00068H","DOIUrl":"https://doi.org/10.1039/D5PM00068H","url":null,"abstract":"Glaucoma is a progressive and chronic eye complication characterized by elevated intraocular pressure (IOP) and consequential optic nerve damage, ultimately leading to blindness. Current therapeutic interventions mainly focus on frequent topical administration of IOP-lowering agents. However, ocular tissues cause prompt clearance of the administered drugs, thereby leading to low bioavailability and reduced patient compliance. This necessitates the development of advanced delivery systems that not only enhance the ocular residence of therapeutic agents but also govern drug release at the site of interest in a spatiotemporally controlled manner. The emergence of nanomedicine and stimuli-responsive delivery systems partially helped to achieve these objectives. These systems show improved permeability, longer ocular retention, or stimuli-responsive drug release (against specific triggers like temperature, pH, ion or enzymes), thereby offering on-demand drug release at the site of interest. This review discusses the anatomy and physiology of ocular tissues, emphasizing their barrier properties for drug delivery in glaucoma therapy. The challenges associated with conventional drug delivery approaches, routes of drug administration, and the need for the development of advanced drug delivery systems have also been emphasized. Furthermore, recent advances in the development of polymeric ophthalmic drug delivery systems and formulation strategies are mentioned with a special emphasis on nanoparticles, in situ gels, and stimuli-responsive systems. Finally, we present our perspectives on scale-up issues, regulatory hurdles, and clinical translation of advanced drug delivery systems.","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 5","pages":" 1050-1077"},"PeriodicalIF":0.0,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2025/pm/d5pm00068h?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intratumoral microbiota: a new perspective in cancer initiation, development, and therapy 肿瘤内微生物群：癌症发生、发展和治疗的新视角

RSC Pharmaceutics Pub Date : 2025-08-01 DOI: 10.1039/D5PM00045A

Huiling Liu, Zhonghui Luo, Fangzhen Luo, Xilian Wang, Hua Wei and Cui-Yun Yu

{"title":"Intratumoral microbiota: a new perspective in cancer initiation, development, and therapy","authors":"Huiling Liu, Zhonghui Luo, Fangzhen Luo, Xilian Wang, Hua Wei and Cui-Yun Yu","doi":"10.1039/D5PM00045A","DOIUrl":"https://doi.org/10.1039/D5PM00045A","url":null,"abstract":"Microbes have been identified as significantly impacting human health. Considerable attention has been focused on how microbiota affects cancer initiation, development, and therapeutic response. Currently, the biological functions of intratumoral microbiota have been preliminarily elucidated in tumors with high microbial abundance. However, the biological roles of the microbiota and their clinical significance in tumors with low microbial abundance, to our knowledge, remain largely unexplored. This gap in understanding is primarily due to the limited sensitivity of current detection technologies. This review provides a detailed examination of intratumoral microbiota characteristics and their interactions with the tumor microenvironment, focusing on the microbiota composition in various systems and its clinical role in different tumor types. Furthermore, the review explores the potential applications of intratumoral microbiota in cancer immunotherapy, including their role as immune enhancers, new drug delivery targets, and anticancer therapeutic agents. In conclusion, these insights may facilitate the use of microbiota for cancer diagnosis, prognosis, and the development of new therapeutic strategies.","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 5","pages":" 865-881"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2025/pm/d5pm00045a?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reversibility of FUS-aided blood–tumor barrier opening for the delivery of therapeutics fus辅助血肿瘤屏障打开治疗药物的可逆性

RSC Pharmaceutics Pub Date : 2025-08-01 DOI: 10.1039/D5PM00088B

Céline Chevaleyre, Sophie Tran, Mylène Richard, Laurène Jourdain, Dimitri Kereselidze, Benoit Jego, Erwan Selingue, Benoit Larrat, Sébastien Mériaux, Nicolas Tournier, Anthony Novell and Charles Truillet

{"title":"Reversibility of FUS-aided blood–tumor barrier opening for the delivery of therapeutics","authors":"Céline Chevaleyre, Sophie Tran, Mylène Richard, Laurène Jourdain, Dimitri Kereselidze, Benoit Jego, Erwan Selingue, Benoit Larrat, Sébastien Mériaux, Nicolas Tournier, Anthony Novell and Charles Truillet","doi":"10.1039/D5PM00088B","DOIUrl":"https://doi.org/10.1039/D5PM00088B","url":null,"abstract":"Focused ultrasound (FUS) offers reversible disruption of the blood–brain barrier (BBB), which enables drug delivery to the brain. However, the impact of FUS on the blood–tumor barrier (BTB) remains largely misunderstood. The reversibility of FUS-induced BTB opening was monitored using PET imaging in a glioblastoma model. C57Bl/6 mice with bilateral GL261-GFP tumors received FUS specifically targeting the right hemisphere, followed by injections of the BBB permeability marker [18F]fluoro-deoxysorbitol (183 Da) or the radiolabeled antibody [18F]avelumab (150 kDa). PET acquisitions were performed at 1 h, 24 h and 72 h post-FUS. The uptake of [18F]avelumab and [18F]fluoro-deoxysorbitol increased immediately after FUS. At 24 h post-FUS, BTB permeability returned to the baseline, as evidenced by consistent [18F]avelumab distribution volumes (VT) between tumors. By 72 h, increased radiotracer uptake indicated tumor progression. These findings highlight the potential of FUS to enhance the delivery of therapeutics to the brain while preserving BTB integrity over time.","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 6","pages":" 1431-1436"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2025/pm/d5pm00088b?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145479556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Accelerating safer administration of medicines to children in low resource settings – bridging stakeholder viewpoints 加快向资源匮乏地区儿童提供更安全的药物管理——弥合利益攸关方的观点

RSC Pharmaceutics Pub Date : 2025-07-29 DOI: 10.1039/D5PM00133A

Sifan Hu, Alka Mukne, Vandana Patravale, Pradeep Behera, Krishnarajan Bangarurajan, Esmerald Hermans, Jennifer Walsh and Smita Salunke

引用次数: 0

Clobetasol propionate and pramoxine hydrochloride loaded nanolipid carrier gel for the treatment of atopic dermatitis† 丙酸氯倍他索与盐酸丙莫辛负载纳米脂载体凝胶治疗特应性皮炎

RSC Pharmaceutics Pub Date : 2025-07-25 DOI: 10.1039/D5PM00048C

Akhil Suresh, K. V. Navyasree, M. S. Sreelakshmi and Vidya Viswanad

{"title":"Clobetasol propionate and pramoxine hydrochloride loaded nanolipid carrier gel for the treatment of atopic dermatitis†","authors":"Akhil Suresh, K. V. Navyasree, M. S. Sreelakshmi and Vidya Viswanad","doi":"10.1039/D5PM00048C","DOIUrl":"https://doi.org/10.1039/D5PM00048C","url":null,"abstract":" Aim. To prepare and evaluate clobetasol propionate (CP) and pramoxine hydrochloride (PH) loaded nanolipid carrier (NLC)-based gel for improved skin permeation in the treatment of atopic dermatitis. Methodology. CP and PH-loaded NLCs were prepared by the melt emulsification ultrasonication technique. In vitro, ex vivo, and in vivo studies in the atopic dermatitis animal model of formulated drug-loaded NLC (DNLC) gel were evaluated. Dermal pharmacokinetic parameters were evaluated by Phoenix WinNonlin software. Results and discussions. DNLC gel was prepared successfully. Skin permeation and retentive property of the DNLC gel showed that CP from the DNLC had a permeability flux of 5.88 μg cm−2 h−1 and an enhancement ratio of 1.92 compared to a CP drug solution, while PH from the DNLC gel had a permeability flux of 9.52 μg cm−2 h−1 and an enhancement ratio of 1.62 compared to a PH drug solution. Dermal pharmacokinetic parameters were determined using WinNonlin software. CP retention at 24 h in stratum corneum, epidermis, and dermis was 4.25 ± 0.02 μg, 75.77 ± 0.01 μg, and 32.04 ± 0.012 μg, respectively, while PH retention at 24 h was 11.82 ± 0.003 μg, 344.0 ± 0.05 μg, and 172.85 ± 0.040 μg, respectively. More CP was retained from the DNLC gel than that from marketed CP cream. In vivo animal studies confirmed the effectiveness of DNLC gel in treating atopic dermatitis compared to commercial cream and individual drug-loaded DNLC gel, decreasing induced disease on a par with marketed CP cream. Epidermal thickness, immunoglobin E (IgE), and absolute eosinophil count (AEC) showed the greatest reduction in the DNLC gel treatment group.","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 5","pages":" 1175-1188"},"PeriodicalIF":0.0,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2025/pm/d5pm00048c?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A new strategy for the extrahepatic delivery of lipid-based nanomedicines: a protein corona-mediated selective targeting system based on an ionizable cationic lipid library 脂质纳米药物肝外递送的新策略：基于可电离阳离子脂质文库的蛋白质冠状介导的选择性靶向系统

RSC Pharmaceutics Pub Date : 2025-07-22 DOI: 10.1039/D5PM00079C

Mahmoud A. Younis, Yusuke Sato, Seigo Kimura and Hideyoshi Harashima

{"title":"A new strategy for the extrahepatic delivery of lipid-based nanomedicines: a protein corona-mediated selective targeting system based on an ionizable cationic lipid library","authors":"Mahmoud A. Younis, Yusuke Sato, Seigo Kimura and Hideyoshi Harashima","doi":"10.1039/D5PM00079C","DOIUrl":"https://doi.org/10.1039/D5PM00079C","url":null,"abstract":"Applying lipid nanoparticle (LNP) technology to ribonucleic acid (RNA) nanomedicines was integral to the success of mRNA vaccines against COVID-19. To expand the power of LNP technology, extrahepatic delivery systems have been developed using specific ligands that target the cells in question. However, recent increases in evidence support targeting without the need to attach specific ligands to nanocarriers. In this review, we focused on protein corona-mediated extrahepatic delivery of nanoparticles as an alternative to classic ligand-mediated active targeting. First, the interaction of LNPs with biological components and the impact that the physicochemical properties of LNPs exert on their biological fate are discussed. Then, we highlight a new system that targets activated hepatic stellate cells (aHSCs) as a successful model achieved through intensive optimization of LNPs based on an ionizable cationic lipid library. We also discuss cumulative evidence that support the ligand-free extrahepatic delivery of nanoparticles to a broad diversity of tissues, such as the spleen, lungs, brain, tumors, kidneys, placenta, pancreas, and bone marrow. In conclusion, we propose protein corona-mediated extrahepatic delivery as a new strategy of active targeting for RNA nanomedicines and inspire the future directions in this area.","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 5","pages":" 982-1002"},"PeriodicalIF":0.0,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2025/pm/d5pm00079c?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systematic screening of excipients to stabilize aerosolized lipid nanoparticles for enhanced mRNA delivery† 系统筛选辅料以稳定雾化脂质纳米颗粒以增强mRNA传递。

RSC Pharmaceutics Pub Date : 2025-07-18 DOI: 10.1039/D5PM00061K

Brittany J. Heiser, Mae M. Lewis, Meysam Mohammadi Zerankeshi, Emily K. Netemeyer, Ashlee M. Hernandez, Alexander E. Marras and Debadyuti Ghosh

{"title":"Systematic screening of excipients to stabilize aerosolized lipid nanoparticles for enhanced mRNA delivery†","authors":"Brittany J. Heiser, Mae M. Lewis, Meysam Mohammadi Zerankeshi, Emily K. Netemeyer, Ashlee M. Hernandez, Alexander E. Marras and Debadyuti Ghosh","doi":"10.1039/D5PM00061K","DOIUrl":"10.1039/D5PM00061K","url":null,"abstract":"Aerosolized lipid nanoparticles (LNPs) delivering mRNA are an attractive strategy for use in local, inhalable therapy to treat patients with lung diseases. However, a major barrier to delivering aerosolized mRNA LNPs is the shear forces encountered during aerosolization. These forces lead to significant morphology changes and subsequent decrease in efficacy of mRNA delivery. To best retain the physicochemical properties of mRNA LNPs during aerosolization, we took a formulation-based strategy to stabilize LNPs. We used a design-of-experiment (DOE) approach to comprehensively screen rationally chosen excipients at multiple concentrations. Excipients were carefully selected based on their use in clinically approved inhaled products or their ability to support lipid membrane properties. These excipients were added to the same mRNA LNP composition after formulation, were subsequently characterized, and used to transfect human lung cells at air–liquid interface. From this systematic screen, we identified that the addition of our lead candidate, poloxamer 188, best stabilizes LNP size throughout aerosolization and enhances mRNA expression after aerosolization. Additional morphological studies of the inclusion of poloxamer 188 in LNPs suggests that the excipient lowers aerosolization induced fusion or aggregation of particles without altering the internal structure. Our results indicate that poloxamer 188 can support aerosolized mRNA LNP delivery by maintaining LNP size and significantly enhancing therapeutic nucleic acid delivery to lung cells.","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 5","pages":" 1139-1154"},"PeriodicalIF":0.0,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12272335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144677128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incorporating AI, in silico, and CRISPR technologies to uncover the potential of repurposed drugs in cancer therapy 结合人工智能、计算机和CRISPR技术，发现癌症治疗中重新利用药物的潜力

RSC Pharmaceutics Pub Date : 2025-07-10 DOI: 10.1039/D5PM00158G

Hend Gamal, Eman Mostafa Shoeib, Areej Hajjaj, Heba Elsafy Abdelaziz Abdullah, Esmail H. Elramy, Doaa Ahmed Abd Ellah, Shorouk Mahmoud El-Sayed and Mohammad Fadl Khder

{"title":"Incorporating AI, in silico, and CRISPR technologies to uncover the potential of repurposed drugs in cancer therapy","authors":"Hend Gamal, Eman Mostafa Shoeib, Areej Hajjaj, Heba Elsafy Abdelaziz Abdullah, Esmail H. Elramy, Doaa Ahmed Abd Ellah, Shorouk Mahmoud El-Sayed and Mohammad Fadl Khder","doi":"10.1039/D5PM00158G","DOIUrl":"https://doi.org/10.1039/D5PM00158G","url":null,"abstract":"Patients with cancer have faced exhausting physical and mental obstacles as a result of traditional treatment methods including chemotherapy and radiation therapy. In cancer, drug repurposing—the use of already-approved medications for novel therapeutic indications—has become a game-changing tactic. This method greatly lowers development costs and durations by utilizing the wealth of safety and pharmacokinetic data available for licensed medications. Large-scale databases and advanced computer techniques enable it to logically find either combinations of traditional medications or selective “non-selective” target medications. Furthermore, repurposing cancer drugs can undergo a significant and profound change thanks to genome-editing technologies like CRISPR-dCas9. It is recognized that there is yet unrealized potential of these advanced methods in further applications. Understanding the pros and cons of these technologies can provide valuable insights for clinical practice and fundamental research projects. This research will explore various innovative methods, including artificial intelligence (AI) algorithms, supervised machine learning (ML), data resources for in silico, microbial clustered regularly interspaced short palindromic repeats-dCas9 (CRISPR-dCas9) based artificial transcription factors, and combination therapy. This comprehensive guide outlines various methods for repurposing drugs, addressing effects, trials, barriers, and potential solutions to aid clinicians and researchers in maximizing efficacy and efficiency.","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 5","pages":" 1019-1033"},"PeriodicalIF":0.0,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2025/pm/d5pm00158g?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0